Neuland Laboratories approves FY26 audited results, ₹34 dividend, director appointment
Neuland Laboratories · Pharmaceuticals & Biotechnology
Key highlights
- Consolidated revenue from operations for FY26 was ₹2,02,298.54 lakhs, against ₹1,47,683.73 lakhs in FY25.
- Consolidated profit before tax for FY26 was ₹48,897.71 lakhs; standalone was ₹48,773.31 lakhs.
- Final dividend of ₹34 per equity share recommended for FY26, record date July 24, 2026.
Why it's rated major development: the year-on-year change is 665% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Change in Directorate
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Neuland Laboratories
- Financial resultsMajor developmentNeuland Q1 net profit up to ₹14,767.31 lakhs; Gland guarantee, Unit 1 capex approved
- Capex / expansionMajor developmentNeuland Laboratories reports Q1 FY 2027 results and announces Gland Pharma partnership
- Capex / expansionMajor developmentNeuland Q1 profit 14,767.31 lakhs vs 1,390.00 lakhs; Gland Pharma sterile API tie-up
- Capex / expansionNotableNeuland Laboratories Limited announces commercial production start of expanded capacities
- Financial resultsMajor developmentNeuland Labs: FY26 results, ₹34 dividend, capacity expansion, new director
Other dividend / buyback / bonus filings this fortnight
- Premco Global Ltd approves Q2 FY 2026-27 results, declares interim dividend, appoints auditor
- Precision Wires India board approves Sept 2026 quarter results and 35% dividend
- Dynamatic Technologies announces Q2 FY27 financial results and interim dividend
- Great Eastern Shipping approves Q2 and H1 results; declares Rs 14.40 interim dividend
- Safari Industries (India) Limited approves Q2 & H1 FY27 results, interim dividend, capex
- IRB Infrastructure Developers announces Q2 & H1 FY27 results and 2nd interim dividend
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.